BioCentury | Mar 29, 2019
Targets & Mechanisms

Next-wave targets at AACR 2019 start filling the blanks in the tumor microenvironment

...expression of OLFM4 is associated with chemoresistance and poor survival in pancreatic cancer. Showa University Peroxiredoxin...
...cell death 1 PD-L1 (B7-H1; CD274) - Programmed cell death 1 ligand 1 PRDX4 - Peroxiredoxin...
BioCentury | Dec 14, 2016
Distillery Therapeutics

Neurology

...SRNX1 expression. Next steps could include promoting SRNX1 expression in animal models of PD. TARGET/MARKER/PATHWAY: Peroxiredoxin...
...Nov. 7, 2016 doi:10.1073/pnas.1608784113 CONTACT: Stuart A. Lipton, Scintillon Institute, San Diego, Calif. email: slipton@ucsd.edu Hongjiang Li Peroxiredoxin...
BioCentury | Sep 1, 2016
Distillery Therapeutics

Therapeutics: Peroxiredoxin 6 (PRDX6); microRNA 371-3p (miR-371-3p)

...growth factor receptor (EGFR) tyrosine kinase activity, to treat non-small cell lung cancer (NSCLC). TARGET/MARKER/PATHWAY: Peroxiredoxin...
BioCentury | Jul 25, 2013
Distillery Therapeutics

Indication: Cancer

...Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Melanoma Peroxiredoxin 2 (PRDX2) Mouse studies...
...with control siRNA. In the same model, mice treated with gliotoxin, a fungal metabolite with peroxiredoxin-like...
BioCentury | May 7, 2009
Distillery Therapeutics

Indication: Cancer

...therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer HER2 (ERBB2; neu); peroxiredoxin...
Items per page:
1 - 5 of 5